Risk of myeloid, lymphoid, and solid malignancies in relatives of patients with CML
| Outcome in relatives . | CML, n = 9491 . | Controls, n = 42 474 . | RR . | 95% CI . |
|---|---|---|---|---|
| Myeloid | ||||
| AML | 8 | 38 | 0.95 | 0.44-2.0 |
| MDS | 0 | 7 | — | — |
| AML/MDS | 8 | 45 | 0.81 | 0.38-1.70 |
| CML | 4 | 11 | 1.62 | 0.37-7.2 |
| MPN | 11 | 44 | 1.14 | 0.59-2.20 |
| Any myeloid malignancy | 23 | 100 | 1.04 | 0.64-1.68 |
| Lymphoid | ||||
| NHL | 35 | 145 | 1.1 | 0.75-1.60 |
| HL | 3 | 26 | 0.52 | 0.16-1.71 |
| CLL | 14 | 52 | 1.2 | 0.69-2.20 |
| WM | 0 | 2 | — | — |
| MM | 11 | 52 | 0.96 | 0.50-1.85 |
| Any lymphoproliferative malignancy | 65 | 276 | 1.07 | 0.80-1.41 |
| ALL | 4 | 9 | 1.98 | 0.61-6.40 |
| Any hematologic malignancy | 92 | 383 | 1.09 | 0.86-1.37 |
| Any solid tumor | 998 | 4312 | 1.04 | 0.97-1.12 |
| Any cancer | 1089 | 4695 | 1.05 | 0.98-1.12 |
| Outcome in relatives . | CML, n = 9491 . | Controls, n = 42 474 . | RR . | 95% CI . |
|---|---|---|---|---|
| Myeloid | ||||
| AML | 8 | 38 | 0.95 | 0.44-2.0 |
| MDS | 0 | 7 | — | — |
| AML/MDS | 8 | 45 | 0.81 | 0.38-1.70 |
| CML | 4 | 11 | 1.62 | 0.37-7.2 |
| MPN | 11 | 44 | 1.14 | 0.59-2.20 |
| Any myeloid malignancy | 23 | 100 | 1.04 | 0.64-1.68 |
| Lymphoid | ||||
| NHL | 35 | 145 | 1.1 | 0.75-1.60 |
| HL | 3 | 26 | 0.52 | 0.16-1.71 |
| CLL | 14 | 52 | 1.2 | 0.69-2.20 |
| WM | 0 | 2 | — | — |
| MM | 11 | 52 | 0.96 | 0.50-1.85 |
| Any lymphoproliferative malignancy | 65 | 276 | 1.07 | 0.80-1.41 |
| ALL | 4 | 9 | 1.98 | 0.61-6.40 |
| Any hematologic malignancy | 92 | 383 | 1.09 | 0.86-1.37 |
| Any solid tumor | 998 | 4312 | 1.04 | 0.97-1.12 |
| Any cancer | 1089 | 4695 | 1.05 | 0.98-1.12 |
ALL, acute lymphoblastic leukemia; CI, confidence interval; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RR, risk ratio; WM, Waldenström macroglobulinemia; —, not computed.